Total : 35 View more »
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory
Targacept, Inc. (TRGT)Q3 2009 Earnings Call TranscriptNovember 5, 2009 5:00 pm ET<a
http://seekingalpha.com/article/171674-targacept-inc-q3-2009-earnings-call-transcript?source=feed
NEW YORK, October 16 (newratings.com) - Analysts at Needham & Co upgrade Targacept (ticker: TRGT) from "hold" to "buy." The target price is set to $26. [more]
http://www.newratings.com/en/main/company_headline.m?id=1977439
Targacept had a net income of $1.3 million in the third quarter, compared to a net loss of $7.6 million a year earlier, according to an earnings announcement. For the year to date, the Winston-Salem drug developer has had a net loss of $13 million, down from a loss of $20.
http://triad.bizjournals.com/triad/stories/2009/11/02/daily82.html?ana=from_rss
Total : 41 View more »
Nov 17, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called an Uptrend for Targacept (NASDAQ:TRGT) on July 08, 2009 at $3.19.
Since then, Targacept has returned 560.3% as of today's recent price of $21.09. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq profit securities trial
Companies: Targacept Inc (TRGT)
Nov 17, 2009 (Close-Up Media via COMTEX) --
Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City on Wednesday, November 18, at 11 a.m. Eastern Standard Time.
In a release, the Company noted event details:
Dr. deBethizy's presentation will be webcast and accessible from the Investor Relations page of the Company's website at targacept.com. The webcast will also be available for replay on the Company's website for at least two weeks following the conference. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start time.
((Comments on this story may be sent to health@closeupmedia.com))
Tags: ceo clinical conference drugs health hotel new_york president
Companies: Targacept Inc (TRGT)
Nov 11, 2009 (SmarTrend(R) Research Reports via COMTEX) --
SmarTrend, the proprietary pattern recognition system, has made available a free sample copy of our premium research report on (NASDAQ:TRGT) at http://www.mysmartrend.com/research/
SmarTrend, our proprietary pattern recognition system, called an Uptrend for Targacept (NASDAQ:TRGT) on July 08, 2009 at $3.19. Since then, Targacept has returned 581.7% as of today's recent price of $21.78.
Want access to these reports and real time alerts? Go to www.tradethetrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq research securities trial
Companies: Targacept Inc (TRGT)
WINSTON-SALEM, N.C., Nov 16, 2009 (BUSINESS WIRE) --
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective with the U.S. market open on Monday, November 23, 2009.
"We are pleased to have earned selection to join the NASDAQ Biotechnology Index, which further validates the tremendous progress Targacept has made during 2009," said J. Donald deBethizy, Ph.D., Targacept's President and Chief Executive Officer. "Our inclusion in this index advances Targacept's visibility as we continue to execute our mission of developing NNR Therapeutics to treat complex diseases and disorders and improve patients' lives."
The NASDAQ Biotechnology Index includes securities of Nasdaq-listed companies that are classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals and meet minimum requirements for market capitalization, average daily trading volume and seasoning as a public company, as well as other eligibility criteria. The index is re-ranked on a semi-annual basis in May and November. Additional information about the NASDAQ Biotechnology Index, including eligibility criteria, is available at https://indexes.nasdaqomx.com/.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders, in support of its vision of building health and restoring independence for patients. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at www.targacept.com.
SOURCE: Targacept, Inc.
Targacept, Inc. Alan Musso, 336-480-2186 VP and CFO alan.musso@targacept.com or Linnden Communications Michelle Linn, 508-362-3087 linnmich@comcast.net
Tags: alzheimers biotechnology capitalization ceo clinical deficit disease drugs index market nasdaq pharmaceuticals president securities
Companies: Targacept Inc (TRGT)
Total : 234 View more »
We are committed to science education through such programs as our Brain Awareness Week lecture series and Triad BioSummer, a unique program for students interested in biotechnology and entrepreneurship. Our employees serve as curriculum advisors, guest speakers, and science fair judges.
LOS ANGELES, Dec 8 (Reuters) - AstraZeneca PLC and Targacept Inc said on Monday that a mid-stage trial of experimental drug AZD3480 failed to demonstrate effectiveness in schizophrenia patients. Shares of Targacept fell 30 percent following the news.
Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of a new class of drugs to treat various central nervous system (CNS) diseases and disorders by selectively targeting neuronal nicotinic receptors, or NNRs.
Total : 36 View more »
Targacept is a biopharmaceutical company that designs, discovers and develops drugs for nervous system diseases and disorders. It targets neuronal nicotinic receptors, or NNRs.
Get the latest TRGT - Targacept Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal finance advice.
Find business news, business blogs, executive career advice, business travel, business culture, company & executive profiles.
http://www.portfolio.com/resources/company-profiles/Targacept-Incorporated-8216
3 hours ago (11/06) Premium Content - please sign up for Ockham PREMIUM to gain full access and to see what Mad Money said about TARGACEPT, INC.TRGT on Mad Money